Mycoplasma genitalium was detected in 21 (14.1%) of 149 vaginal swab samples and in 1 (0.7%) of 149 throat washing samples from female sex workers during 2013-2014 in Japan. Prevalences of M. genitalium with macrolide resistance-associated 23S rRNA mutations and fluoroquinolone resistance-associated parC alterations were 47.1% and 36.8%, respectively.
Mycoplasma genitalium was detected in 21 (14.1%) of 149 vaginal swab samples and in 1 (0.7%) of 149 throat washing samples from female sex workers during 2013-2014 in Japan. Prevalences of M. genitalium with macrolide resistance-associated 23S rRNA mutations and fluoroquinolone resistance-associated parC alterations were 47.1% and 36.8%, respectively.
F
or Mycoplasma genitalium infections, azithromycin regimens have been considered first-line treatments, and fluoroquinolone regimens, including those of moxifloxacin and sitafloxacin, have been effective second-line treatments (1) . However, the proportion of M. genitalium harboring macrolide or fluoroquinolone resistance-associated mutations has been increasing in male and female patients with M. genitalium infections (2) (3) (4) (5) , and treating M. genitalium infections with current antimicrobial chemotherapies is increasingly difficult (5, 6) .
The prevalence of M. genitalium infections in women at low risk for sexually transmitted infections (STIs) is reportedly 2.0%, with the range for most cohorts being <1%-5%. In high-risk populations, the prevalence is 0%-42% (7). For female sex workers (FSWs), the range of M. genitalium prevalence rates is reportedly 12%-26% (7-10). FSWs could be a reservoir of M. genitalium infections, but little is known about drug resistance in M. genitalium in FSWs.
In this study, vaginal swab and throat washing samples collected from 149 FSWs were examined for the presence of M. genitalium. Positive specimens were then tested for drug resistance-associated mutations in the M. genitalium DNA.
The Study
This cross-sectional prospective study was approved by the Institutional Review Board of the Graduate School of Medicine, Gifu University, Japan (reference number 22-11). A total of 149 FSWs who attended Hoshina Clinic, Kyoto, Japan, for regular screening for STIs from August 2013 through January 2014 were enrolled in this study after informed consent was obtained. The women were 19-47 years of age (mean 29 years). All performed fellatio on their clients without use of condoms. Six (4.0%) had received antimicrobial drug treatment (i.e., azithromycin, clarithromycin, ceftriaxone, or amoxicillin) for gonococcal or chlamydial infections during the 3 months before visiting the clinic. Sixty-five (43.6%) had histories of STIs, including gonococcal infections, chlamydial infections, genital condyloma, genital herpes, and syphilis. Other sociodemographic information, sexual history, or HIV serologic status was not obtained from most participants. At clinic visits, all were asymptomatic. On genital examination, however, genital herpes was found in 1 (0.7%), and mucopurulent vaginal discharge was found in 3 (2.0%).
Vaginal swab and throat washing samples were collected from all 149 women, as previously recommended (11) . These specimens were tested by using Cobas 4800 CT/NG (Roche Molecular Systems, Pleasanton, CA, USA) to detect Chlamydia trachomatis and Neisseria gonorrhoeae. The specimens were also tested for M. genitalium, M. hominis, Ureaplasma urealyticum, and U. parvum, as previously recommended (12). The DNA specimens were then stored at -80°C. The 1 throat washing positive for M. genitalium was tested by PCR with primers specific for the 23S rRNA genes of the genital mycoplasmas, which were used in the PCR-based assay. The PCR product was sequenced, and its sequence was compared to the 23S rRNA genes of M. genitalium and M. pneumoniae (13, 14) .
A total of 6 bacterial species were detected in the samples (Table 1) . M. genitalium was detected in the vaginal swab samples from 21 FSWs (14.1%, 95% CI 8.5%-19.7%). M. genitalium was also detected in a throat washing sample from 1 FSW (0.7%, 95% CI 0%-2.0%), whose vaginal swab sample was negative for M. genitalium. The sequence of the PCR product amplified from the DNA from the throat washing specimens aligned with that of the 23S rRNA gene of M. genitalium but not with that of M. pneumoniae.
The prevalence of M. genitalium in vaginal swab samples from the asymptomatic FSWs in this study was similar to that reported in FSWs worldwide (7) (8) (9) (10) . The FSWs enrolled in this study were at high risk for pharyngeal STIs. However, M. genitalium was found in only 1 throat washing sample and was not detected in throat washing samples obtained from 403 FSWs in our previous study (11) . The prevalence of M. genitalium in the genitalia of FSWs would be expected to be high, whereas the prevalence of mycoplasma in the pharynx has been extremely low.
For the 21 vaginal swab samples and 1 throat washing sample that were positive for M. genitalium from the 22 FSWs, the portion of the 23S rRNA gene, including A-2058 and A-2059 in the 23S rRNA gene of Escherichia coli, and the region corresponding to the quinolone resistance-determining regions of the E. coli gyrA and parC genes were amplified from the stored DNA specimens by PCR, and sequencing of the PCR products was performed, as reported previously (4). The 6 FSWs to whom antibiotics had been administered 3 months before this study were not included in these 22 FSWs. Table 2 shows the results of analyses of these 22 specimens for the drug resistance-associated alterations. Five vaginal swab specimens and the 1 throat washing specimen could not be analyzed because their stored DNA yielded no reliable PCR products. The storage of the frozen specimens likely had degraded the quality of the DNA, or the specimens might have contained low bacterial loads of M. genitalium. However, for samples for which genes could be analyzed, 8 (47.1%, 95% CI 23.4%-70.8%) of 17 vaginal swab samples had macrolide resistance-associated 23S rRNA mutations, and 7 (36.8%, 95% CI 15.1%-58.5%) of 19 samples had fluoroquinolone resistance-associated parC alterations. For 21 vaginal swab samples, no fluoroquinolone resistance-associated gyrA alterations were found. Four of 16 vaginal swab samples that could be analyzed for the 23S rRNA gyrA and the parC genes showed drug resistance-associated alterations in both genes (25.0%, 95% CI 3.8%-46.2%).
In Australia and the United Kingdom, the proportions of M. genitalium harboring macrolide resistance-associated mutations in clinical specimens from male and female patients with M. genitalium infections ranged from 36.1% to 43.4% (2, 3, 5) , but proportions of the mycoplasma harboring the fluoroquinolone resistance-associated amino acid changes in gyrA or parC ranged from 4.5% to 15.4% (2, 3) . For Japan, we reported that drug resistance-associated 23S rRNA mutations and parC alterations were observed in 
